These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 27989789)

  • 1. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study.
    Clementy N; Challal F; Marijon E; Boveda S; Defaye P; Leclercq C; Deharo JC; Sadoul N; Klug D; Piot O; Gras D; Bordachar P; Algalarrondo V; Fauchier L; Babuty D;
    Heart Rhythm; 2017 Feb; 14(2):211-217. PubMed ID: 27989789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial.
    Gasparini M; Lunati MG; Proclemer A; Arenal A; Kloppe A; Martínez Ferrer JB; Hersi AS; Gulaj M; Wijffels MCE; Santi E; Manotta L; Varma N
    JACC Clin Electrophysiol; 2017 Nov; 3(11):1275-1282. PubMed ID: 29759624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
    Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication.
    Boersma LV; Barr CS; Burke MC; Leon AR; Theuns DA; Herre JM; Weiss R; Kremers MS; Neuzil P; Husby MP; Carter N; Stivland TM; Gold MR;
    Heart Rhythm; 2017 Mar; 14(3):367-375. PubMed ID: 27890798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
    Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
    Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
    Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programming implantable cardioverter-defibrillator therapy zones to high ranges to prevent delivery of inappropriate device therapies in patients with primary prevention: results from the RISSY-ICD (Reduction of Inappropriate ShockS bY InCreaseD zones) trial.
    Cay S; Canpolat U; Ucar F; Ozeke O; Ozcan F; Topaloglu S; Aras D
    Am J Cardiol; 2015 May; 115(9):1235-43. PubMed ID: 25765588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.
    Greenlee RT; Go AS; Peterson PN; Cassidy-Bushrow AE; Gaber C; Garcia-Montilla R; Glenn KA; Gupta N; Gurwitz JH; Hammill SC; Hayes JJ; Kadish A; Magid DJ; McManus DD; Multerer D; Powers JD; Reifler LM; Reynolds K; Schuger C; Sharma PP; Smith DH; Suits M; Sung SH; Varosy PD; Vidaillet HJ; Masoudi FA
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29581222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.
    Gold MR; Lambiase PD; El-Chami MF; Knops RE; Aasbo JD; Bongiorni MG; Russo AM; Deharo JC; Burke MC; Dinerman J; Barr CS; Shaik N; Carter N; Stoltz T; Stein KM; Brisben AJ; Boersma LVA;
    Circulation; 2021 Jan; 143(1):7-17. PubMed ID: 33073614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
    Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial.
    Ruwald MH; Zareba W; Jons C; Zhang C; Ruwald AC; Olshansky B; McNitt S; Bloch Thomsen PE; Shoda M; Merkely B; Moss AJ; Kutyifa V
    Circulation; 2013 Aug; 128(7):694-701. PubMed ID: 23881862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
    Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study.
    Schwab JO; Bonnemeier H; Kleemann T; Brachmann J; Fischer S; Birkenhauer F; Eberhardt F
    Clin Res Cardiol; 2015 Dec; 104(12):1021-32. PubMed ID: 26002818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel ICD Programming and Inappropriate ICD Therapy in CRT-D Versus ICD Patients: A MADIT-RIT Sub-Study.
    Kutyifa V; Daubert JP; Schuger C; Goldenberg I; Klein H; Aktas MK; McNitt S; Stockburger M; Merkely B; Zareba W; Moss AJ
    Circ Arrhythm Electrophysiol; 2016 Jan; 9(1):e001965. PubMed ID: 26743237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
    Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
    Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.